Business
Janux Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights
R&D Day highlighted TRACTr, TRACIr, and ARM pipeline progress and best-in-class potential of novel bispecific ARM platform for autoimmune diseases Enrollment
About this update from Janux Therapeutics, Inc.
[{"type":"text","content":"\n\nR&D Day highlighted TRACTr, TRACIr, and ARM pipeline progress and best-in-class potential of novel bispecific ARM platform for autoimmune diseases\n\n\n\nEnrollment ongoing for JANX007 and JANX008\n\n\n\nUpdates on JANX007 and JANX008 expected in the second half of 2025\n\n\n\nFirst patient dosed in lead collaboration program triggers $10 million milestone payment from Merck\n\n\n\n$996.0 million in cash, cash equivalents, and short-term investments at end of second quarter 2025\n\n\n\n SAN DIEGO--(BUSINESS WIRE)--\nJanux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technologies to its Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms, today reported financial results for the second quarter ended June 30, 2025, and provided a business update.\n\n\n“The recent expansion of our TRACTr, TRACIr, and ARM development programs displays our ability to enact a strategy that attempts to both maximize the benefit and value of our current clinical programs, including JANX007, while continuing to advance other differentiated candidates in oncology and autoimmune disease,” said David Campbell, Ph.D., President and CEO of Janux. “We look forward to additional clinical data from JANX007 and JANX008 expected in the second half of 2025.”\n\n\nRECENT BUSINESS HIGHLIGHTS AND FUTURE MILESTONES:\n\n\n\nR&D Day highlighted pipeline progress and novel bispecific platform in autoimmune disease.\nIn July 2025, Janux management presented multiple product candidates identified from its preclinical pipeline to move towards clinical trials.\n\n\n\n\nA PSMA-TRACIr designed to be combined with potentially best-in-treatment asset, JANX007, and provide CD28 co-stimulation to further differentiate depth and durability of patient responses.\n\n\n\nA TROP2-TRACTr added a first-in-class opportunity targeting multiple solid tumors with preclinical data supporting differentiated safety and efficacy potential.\n\n\n\nA CD19-ARM displayed rapid, deep and durable B-cell depletion in periphery and tissues with a prolonged memory B cell reset while maintaining a large safety window in non-human primates.\n\n\n\n\nJANX007 continues to enroll in the first-in-human ...